Conference abstract · 2021
Conference abstractPublished 20 Aug 2018
Decoding how key stakeholders drive biosimilar adoption
Stanford University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
When preparing to launch a biosimilar, key distinctions from traditional biologic product launches and increased uncertainty across regulatory, legal and commercial spheres make navigating this landscape especially challenging. It is critical to align incentives of key stakeholders (providers, patients, payers, pharmacists and procurement) as they each can play a critical role in driving/delaying biosimilar uptake. Achieving commercial success in biosimilarâ??s therefore requires a new approach to understand the market complexity and to engage these stakeholders. Biosimilar developers need to have a strategic plan for forecasting and market research to effectively maximize the commercial opportunity. Forecasting biosimilar uptake can be daunting as market events can result in dramatic swings in expected uptake. As a result, a biosimilar forecast should not be an exercise of determining a single share point or uptake curve -rather it should be about understanding the scenarios that could unfold the forecast in each scenario and understanding the key drivers that will determine the success or failure of a biosimilar. Market research can identify opportunities a manufacturer (innovator or biosimilar) can influence across stakeholders. Faced with this paradigm shift, manufacturers have struggled to understand the right questions to understand the complexities of the market some they should consider: (1) What are the key drivers and barriers to uptake across stakeholders? (2) What levers are most successful at encouraging biosimilar adoption? (3) What archetype markets are most appropriate to use as analogs? (4) How can biosimilars differentiate themselves when clinical differentiation is not possible? (5) What are the most successful contract pricing strategies in a market with biosimilar competition? These questions are critical to address through tailored research techniques and modeling to effectively map the interplay of the incentives of each stakeholder type.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 20 Aug 2018
Decoding how key stakeholders drive bio similar adoption
Conference abstract · 3 Apr 2023
The end of phase 3 systematic confirmatory clinical trials in biosimilars development, are all stakeholders aligned?
Research article · 24 Aug 2021
Shepherding Into the Epoch of Communicating With Stakeholders: Need to Embrace the Adoption of IFRs in Oman
Research article · 26 Jul 2019
Malaysian Stakeholders Intention to Adopt Genetic Testing
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Tucker Herbert”

